|
US6150328A
(en)
*
|
1986-07-01 |
2000-11-21 |
Genetics Institute, Inc. |
BMP products
|
|
US5811523A
(en)
|
1988-11-10 |
1998-09-22 |
Trinchieri; Giorgio |
Antibodies to natural killer stimulatory factor
|
|
US5457038A
(en)
*
|
1988-11-10 |
1995-10-10 |
Genetics Institute, Inc. |
Natural killer stimulatory factor
|
|
US5780597A
(en)
*
|
1989-12-22 |
1998-07-14 |
Hoffmann-La Roche Inc. |
Monoclonal antibodies to cytotoxic lymphocyte maturation factor
|
|
DK0433827T3
(da)
*
|
1989-12-22 |
1998-09-28 |
Hoffmann La Roche |
Cytotoksisk lumfocytmodningsfaktor
|
|
US20080070842A1
(en)
*
|
1991-11-04 |
2008-03-20 |
David Israel |
Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
|
|
KR100259827B1
(ko)
|
1991-11-04 |
2000-06-15 |
브루스 엠. 에이센, 토마스 제이 데스로저 |
재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
|
|
US6399379B1
(en)
|
1992-09-29 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of interleukin 12 p35 subunit expression
|
|
CA2125763C
(en)
*
|
1993-07-02 |
2007-08-28 |
Maurice Kent Gately |
P40 homodimer of interleukin-12
|
|
US6291206B1
(en)
|
1993-09-17 |
2001-09-18 |
Genetics Institute, Inc. |
BMP receptor proteins
|
|
EP0733109B9
(en)
*
|
1993-12-07 |
2006-07-05 |
Genetics Institute, LLC |
Bmp-12, bmp-13 and tendon-inducing compositions thereof
|
|
US6706264B1
(en)
|
1994-03-14 |
2004-03-16 |
Genetics Institute, Llc |
Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
|
|
ZA95960B
(en)
*
|
1994-03-14 |
1995-10-10 |
Genetics Inst |
Use of interleukin-12 antagonists in the treatment of autoimmune diseases
|
|
US5571515A
(en)
|
1994-04-18 |
1996-11-05 |
The Wistar Institute Of Anatomy & Biology |
Compositions and methods for use of IL-12 as an adjuvant
|
|
US5635182A
(en)
*
|
1994-06-16 |
1997-06-03 |
Genetics Institute, Inc. |
Method of detecting ligand interactions
|
|
DE69519454T2
(de)
|
1994-07-14 |
2001-05-03 |
Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama |
Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
|
|
TW581771B
(en)
*
|
1994-11-15 |
2004-04-01 |
Hayashibara Biochem Lab |
Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
|
|
JP2724987B2
(ja)
|
1994-11-15 |
1998-03-09 |
株式会社林原生物化学研究所 |
インターフェロン−γの産生を誘導するポリペプチド
|
|
JP4004088B2
(ja)
|
1995-09-26 |
2007-11-07 |
株式会社林原生物化学研究所 |
免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
|
|
US7135458B1
(en)
|
1995-11-15 |
2006-11-14 |
Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo |
Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
|
|
US5674483A
(en)
*
|
1995-01-31 |
1997-10-07 |
National Jewish Medical And Research Center |
Treatment for diseases involving inflammation
|
|
JP2000510813A
(ja)
*
|
1995-02-06 |
2000-08-22 |
ジェネテイックス・インスティテュート・インコーポレイテッド |
Ｉｌ−１２用処方
|
|
US5891680A
(en)
*
|
1995-02-08 |
1999-04-06 |
Whitehead Institute For Biomedical Research |
Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
|
|
US5872154A
(en)
*
|
1995-02-24 |
1999-02-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant adenovirus
|
|
US6372208B1
(en)
|
1999-09-28 |
2002-04-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
|
US6251957B1
(en)
|
1995-02-24 |
2001-06-26 |
Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
|
US5853714A
(en)
*
|
1995-03-27 |
1998-12-29 |
Genetics Institute, Inc. |
Method for purification of IL-12
|
|
US6509313B1
(en)
*
|
1996-02-28 |
2003-01-21 |
Cornell Research Foundation, Inc. |
Stimulation of immune response with low doses of cytokines
|
|
GB9609932D0
(en)
*
|
1996-05-13 |
1996-07-17 |
Hoffmann La Roche |
Use of IL-12 and IFN alpha for the treatment of infectious diseases
|
|
EP0931156A2
(en)
*
|
1996-10-18 |
1999-07-28 |
Valentis Inc. |
Gene expression and delivery systems and uses
|
|
WO1998017689A2
(en)
*
|
1996-10-18 |
1998-04-30 |
Valentis Inc. |
Il-12 gene expression and delivery systems and uses
|
|
CA2745736C
(en)
*
|
1996-10-23 |
2016-11-22 |
The Trustees Of The University Of Pennsylvania |
Immunotherapy and improved vaccines
|
|
US5994104A
(en)
*
|
1996-11-08 |
1999-11-30 |
Royal Free Hospital School Of Medicine |
Interleukin-12 fusion protein
|
|
WO1998041229A1
(en)
*
|
1997-03-19 |
1998-09-24 |
F. Hoffmann-La Roche Ag |
USE OF IL-12p40 AS IMMUNOSTIMULANT
|
|
EP1030681A4
(en)
*
|
1997-11-03 |
2001-07-04 |
Wistar Inst |
METHOD AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS AND TREATING CANCER
|
|
ES2221717T3
(es)
|
1997-12-08 |
2005-01-01 |
Emd Lexigen Research Center Corp. |
Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
|
|
DE69916022T2
(de)
*
|
1998-01-23 |
2004-09-02 |
Genetics Institute, LLC, Cambridge |
Methode zur Verwendung von IL-11 zur Verstärkung der zellvermittelten Immunität zur Behandlung verschiedener viraler und parasitärer Infektionen und Krebs
|
|
US7026456B1
(en)
|
1998-01-23 |
2006-04-11 |
Hoffman-La Roche, Inc. |
Antibodies against human IL-12
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
US7247442B1
(en)
|
1998-05-12 |
2007-07-24 |
Human Genome Sciences, Inc. |
Antibodies to HHPEN62 polypeptide
|
|
US6375944B1
(en)
|
1998-09-25 |
2002-04-23 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
|
|
US6448081B1
(en)
*
|
2001-05-07 |
2002-09-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of interleukin 12 p40 subunit expression
|
|
US6727224B1
(en)
*
|
1999-02-01 |
2004-04-27 |
Genetics Institute, Llc. |
Methods and compositions for healing and repair of articular cartilage
|
|
US6570002B1
(en)
*
|
1999-02-26 |
2003-05-27 |
The Johns Hopkins University |
Inhibitor of programmed cell death
|
|
US6800460B1
(en)
|
1999-03-11 |
2004-10-05 |
Schering Corporation |
Mammalian cytokine complexes
|
|
JP2003508013A
(ja)
*
|
1999-03-12 |
2003-03-04 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
５０個のヒト分泌タンパク質
|
|
AU3517000A
(en)
*
|
1999-03-12 |
2000-10-04 |
Human Genome Sciences, Inc. |
50 human secreted proteins
|
|
WO2000061628A1
(en)
*
|
1999-04-09 |
2000-10-19 |
Human Genome Sciences, Inc. |
49 human secreted proteins
|
|
WO2000055201A1
(en)
*
|
1999-03-12 |
2000-09-21 |
Human Genome Sciences, Inc. |
49 human secreted proteins
|
|
AU3767000A
(en)
*
|
1999-03-26 |
2000-10-16 |
Human Genome Sciences, Inc. |
50 human secreted proteins
|
|
EP1171462A2
(en)
*
|
1999-03-26 |
2002-01-16 |
Human Genome Sciences, Inc. |
49 human secreted proteins
|
|
AU4066800A
(en)
*
|
1999-04-01 |
2000-10-23 |
Genetics Institute Inc. |
Angiopoietin-like proteins, crisp proteins and polynucleotides encoding same
|
|
EP1203018A1
(en)
*
|
1999-07-21 |
2002-05-08 |
Human Genome Sciences, Inc. |
26 human prostate and prostate cancer associated proteins
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
WO2001010912A1
(en)
|
1999-08-09 |
2001-02-15 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
|
JP2003507036A
(ja)
*
|
1999-08-16 |
2003-02-25 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
レチノイドレセプター相互作用ポリヌクレオチド、ポリペプチド、および抗体
|
|
JP2003533968A
(ja)
*
|
1999-09-03 |
2003-11-18 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
免疫グロブリンスーパーファミリーポリヌクレオチド、ポリペプチド、および抗体
|
|
CA2384672A1
(en)
*
|
1999-09-09 |
2001-03-15 |
Human Genome Sciences, Inc. |
Steroid hormone receptor polynucleotides, polypeptides, and antibodies
|
|
AU7603800A
(en)
*
|
1999-09-24 |
2001-04-24 |
Human Genome Sciences, Inc. |
32 human secreted proteins
|
|
EP1223990B1
(en)
|
1999-10-15 |
2004-07-28 |
Genetics Institute, LLC |
Formulations of hyaluronic acid for delivery of osteogenic proteins
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
US7115712B1
(en)
*
|
1999-12-02 |
2006-10-03 |
Maxygen, Inc. |
Cytokine polypeptides
|
|
EP1248801A4
(en)
*
|
2000-01-18 |
2003-08-27 |
Human Genome Sciences Inc |
HUMANE POLYNUCLEOTIDES, POLYPEPTIDES AND ANTIBODIES
|
|
WO2001055448A1
(en)
*
|
2000-01-31 |
2001-08-02 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
AU2001238585A1
(en)
*
|
2000-02-24 |
2001-09-03 |
Human Genome Sciences, Inc. |
Human polynucleotides, polypeptides, and antibodies
|
|
WO2001070804A1
(en)
*
|
2000-03-17 |
2001-09-27 |
Human Genome Sciences, Inc. |
7 human ovarian and ovarian cancer associated proteins
|
|
US20030166044A1
(en)
*
|
2000-03-31 |
2003-09-04 |
Kenneth Jacobs |
Novel proteins
|
|
CA2404074A1
(en)
*
|
2000-04-03 |
2001-10-11 |
Human Genome Sciences, Inc. |
Human polynucleotides, polypeptides, and antibodies
|
|
AU2001253362A1
(en)
*
|
2000-04-13 |
2001-10-30 |
Smith Kline Beecham Corporation |
Novel compounds
|
|
NZ523122A
(en)
*
|
2000-06-22 |
2004-06-25 |
Smithkline Beecham Corp |
Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
|
|
CZ2003214A3
(cs)
*
|
2000-06-29 |
2003-08-13 |
Merck Patent Gmbh |
Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
|
|
US6902734B2
(en)
*
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
|
EP1313761A4
(en)
*
|
2000-08-28 |
2005-01-26 |
Human Genome Sciences Inc |
18 HUMAN, SPECIFIC PROTEINS
|
|
US20030082233A1
(en)
*
|
2000-12-01 |
2003-05-01 |
Lyons Karen M. |
Method and composition for modulating bone growth
|
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
|
US7226587B2
(en)
*
|
2001-06-01 |
2007-06-05 |
Wyeth |
Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
|
|
TWI267378B
(en)
*
|
2001-06-08 |
2006-12-01 |
Wyeth Corp |
Calcium phosphate delivery vehicles for osteoinductive proteins
|
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
ATE471946T1
(de)
|
2002-12-17 |
2010-07-15 |
Merck Patent Gmbh |
Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
|
|
US7939058B2
(en)
|
2003-07-03 |
2011-05-10 |
University Of Southern California |
Uses of IL-12 in hematopoiesis
|
|
TW200518767A
(en)
*
|
2003-09-12 |
2005-06-16 |
Wyeth Corp |
Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
|
|
CA2552590A1
(en)
*
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
US20040260068A1
(en)
*
|
2004-02-26 |
2004-12-23 |
Naoya Tsurushita |
Humanized chicken antibodies
|
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
|
CA2591813A1
(en)
|
2004-12-21 |
2006-06-29 |
Centocor, Inc. |
Anti-il-12 antibodies, epitopes, compositions, methods and uses
|
|
US20060166251A1
(en)
*
|
2005-01-26 |
2006-07-27 |
Archambault Joanne M |
Use of sFRPs as markers of BMP activity
|
|
JP2008534607A
(ja)
*
|
2005-03-30 |
2008-08-28 |
ワイス |
Ｂｍｐを投与することによって毛髪の成長を刺激するための方法
|
|
SI1966238T1
(sl)
*
|
2005-12-30 |
2012-08-31 |
Merck Patent Gmbh |
Variante interlevkina-12P40 z izboljšano stabilnostjo
|
|
WO2008070647A1
(en)
*
|
2006-12-07 |
2008-06-12 |
Wyeth |
Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
|
|
EP2248903A1
(en)
|
2009-04-29 |
2010-11-10 |
Universitat Autònoma De Barcelona |
Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
EP2571516B1
(en)
|
2010-05-18 |
2017-11-15 |
Neumedicines, Inc |
Il-12 formulations for enhancing hematopoiesis
|
|
WO2012174056A1
(en)
|
2011-06-13 |
2012-12-20 |
Neumedicines, Inc. |
Mitigation of cutaneous injury with il-12
|
|
EP2736530B1
(en)
|
2011-07-27 |
2018-06-06 |
Neumedicines, Inc |
Use of il-12 to generate endogenous erythropoietin
|
|
US9636381B2
(en)
|
2012-01-18 |
2017-05-02 |
Neumedicines, Inc. |
Methods for radiation protection by administering IL-12
|
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
|
EP2940128A1
(en)
|
2014-04-30 |
2015-11-04 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Adenovirus comprising an albumin-binding moiety
|
|
AU2016334401A1
(en)
|
2015-10-10 |
2018-04-26 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
|
EP3436477A2
(en)
|
2016-03-29 |
2019-02-06 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
|
|
TW201922780A
(zh)
*
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
|
|
WO2019220412A2
(en)
|
2018-05-18 |
2019-11-21 |
Janssen Biotech, Inc. |
Safe and effective method of treating lupus with anti-il12/il23 antibody
|
|
HUE063462T2
(hu)
|
2018-09-24 |
2024-01-28 |
Janssen Biotech Inc |
A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
|
|
EP3972690A4
(en)
|
2019-05-23 |
2023-07-05 |
Janssen Biotech, Inc. |
METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
|
|
CA3183927A1
(en)
|
2020-05-21 |
2021-11-25 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
IL312221A
(en)
|
2021-10-20 |
2024-06-01 |
Synthekine Inc |
Heterodimeric fc cytokines and uses thereof
|
|
WO2023070038A2
(en)
*
|
2021-10-20 |
2023-04-27 |
Synthekine, Inc. |
Human il-12p40 variants and uses thereof
|